U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C11H12N2S.ClH
Molecular Weight 240.7538
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVAMISOLE HYDROCHLORIDE

SMILES

c1ccc(cc1)[C@@]2([H])CN3CCSC3=N2.Cl

InChI

InChIKey=LAZPBGZRMVRFKY-HNCPQSOCSA-N
InChI=1S/C11H12N2S.ClH/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10;/h1-5,10H,6-8H2;1H/t10-;/m1./s1

HIDE SMILES / InChI
Levamisole (the trade name Ergamisol), an anthelminthic drug with immunological properties. It also has antitumor activity when administered with 5-fluorouracil in patients with Duke's C colorectal carcinoma; however, this use was discontinued. The mechanism of the antitumor effect is unknown but has been postulated to be related to levamisole's immunomodulatory properties. Levamisole can stimulate antibody formation to various antigens, enhance T-cell responses by stimulating T-cell activation and proliferation, potentiate monocyte and macrophage functions including phagocytosis, chemotaxis and increases motility, adherence, and chemotaxis. Levamisole inhibits alkaline phosphatase and possesses cholinergic activity. The mechanism of action of levamisole as an antiparasitic agent, for example, to treat ascariasis, relates to its agonistic activity to L-subtype nicotinic acetylcholine receptors in nematode muscles. In addition, levamisole was studied for preventing relapses of the steroid-sensitive idiopathic nephrotic syndrome (SSINS). It was shown, that alone or in combination with steroids, the drug can prolong the time to relapse and prevented recurrence during one year of treatment. However, these studies also were also discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P05186|||Q5BKZ5
Gene ID: 249.0
Gene Symbol: ALPL
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ERGAMISOL

Approved Use

Unknown

Launch Date

6.4558078E11
Curative
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.76 mg/L
150 mg unknown, oral
dose: 150 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.93 mg/L
5 mg/kg bw single, oral
dose: 5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
1.53 mg/L
5 mg/kg bw single, oral
dose: 5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.84 mg/L
5 mg/kg bw single, oral
dose: 5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
0.72 mg/L
150 mg unknown, oral
dose: 150 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.75 mg/L
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.74 mg/L
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
1.28 mg/L
5 mg/kg bw single, oral
dose: 5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.97 mg/L
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
0.69 mg/L
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.53 mg/L
2.5 mg/kg bw 1 times / 2 days multiple, oral
dose: 2.5 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.15 mg × h/L
150 mg unknown, oral
dose: 150 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
13.78 mg × h/L
5 mg/kg bw single, oral
dose: 5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
18.96 mg × h/L
5 mg/kg bw single, oral
dose: 5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
19.69 mg × h/L
5 mg/kg bw single, oral
dose: 5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
3.07 mg × h/L
150 mg unknown, oral
dose: 150 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.48 mg × h/L
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.1 mg × h/L
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
6.88 mg × h/L
5 mg/kg bw single, oral
dose: 5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7.16 mg × h/L
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
7.44 mg × h/L
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.54 mg × h/L
2.5 mg/kg bw 1 times / 2 days multiple, oral
dose: 2.5 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.4 h
150 mg unknown, oral
dose: 150 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.65 h
5 mg/kg bw single, oral
dose: 5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
5.75 h
5 mg/kg bw single, oral
dose: 5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.58 h
5 mg/kg bw single, oral
dose: 5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
5.56 h
150 mg unknown, oral
dose: 150 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.85 h
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.88 h
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
2.71 h
5 mg/kg bw single, oral
dose: 5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.72 h
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
6.04 h
2.5 mg/kg bw single, oral
dose: 2.5 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.07 h
2.5 mg/kg bw 1 times / 2 days multiple, oral
dose: 2.5 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
49%
150 mg unknown, oral
dose: 150 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
49%
150 mg unknown, oral
dose: 150 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
LEVAMISOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
50 mg 2 times / day multiple, oral
Dose: 50 mg, 2 times / day
Route: oral
Route: multiple
Dose: 50 mg, 2 times / day
Sources:
unhealthy, 15 years
n = 1
Health Status: unhealthy
Age Group: 15 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Epidermal necrolysis...
AEs leading to
discontinuation/dose reduction:
Epidermal necrolysis (1 patient)
Sources:
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Age Group: 34 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Myopathy, Leukocytoclastic vasculitis...
AEs leading to
discontinuation/dose reduction:
Myopathy (1 patient)
Leukocytoclastic vasculitis (1 patient)
Sources:
250 mg single, intravenous
Overdose
Dose: 250 mg
Route: intravenous
Route: single
Dose: 250 mg
Sources:
unknown, 52 years
n = 1
Health Status: unknown
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
Other AEs: Adverse event...
Other AEs:
Adverse event (grade 5)
Sources:
3.5 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 3.5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 3.5 mg/kg, 1 times / day
Sources:
unhealthy, 7-12 years
n = 28
Health Status: unhealthy
Condition: pediculosis capitis
Age Group: 7-12 years
Sex: F
Population Size: 28
Sources:
150 mg 1 times / week multiple, oral
Dose: 150 mg, 1 times / week
Route: oral
Route: multiple
Dose: 150 mg, 1 times / week
Sources:
unhealthy
Disc. AE: Agranulocytosis...
AEs leading to
discontinuation/dose reduction:
Agranulocytosis
Sources:
AEs

AEs

AESignificanceDosePopulation
Epidermal necrolysis 1 patient
Disc. AE
50 mg 2 times / day multiple, oral
Dose: 50 mg, 2 times / day
Route: oral
Route: multiple
Dose: 50 mg, 2 times / day
Sources:
unhealthy, 15 years
n = 1
Health Status: unhealthy
Age Group: 15 years
Sex: M
Population Size: 1
Sources:
Leukocytoclastic vasculitis 1 patient
Disc. AE
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Age Group: 34 years
Sex: F
Population Size: 1
Sources:
Myopathy 1 patient
Disc. AE
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Age Group: 34 years
Sex: F
Population Size: 1
Sources:
Adverse event grade 5
250 mg single, intravenous
Overdose
Dose: 250 mg
Route: intravenous
Route: single
Dose: 250 mg
Sources:
unknown, 52 years
n = 1
Health Status: unknown
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
Agranulocytosis Disc. AE
150 mg 1 times / week multiple, oral
Dose: 150 mg, 1 times / week
Route: oral
Route: multiple
Dose: 150 mg, 1 times / week
Sources:
unhealthy
PubMed

PubMed

TitleDatePubMed
Multifocal demyelinative leukoencephalopathy associated with 5-fluorouracil and levamisole.
2000
Levamisole induced apoptosis in cultured vascular endothelial cells.
2000 Dec
Non-corticosteroid treatment for nephrotic syndrome in children.
2001
[Clinical and immunological characteristics and specific features of the treatment of patients with recurrent sarcoidosis of respiratory organs].
2001
Prognostic histological and immune markers of renal cell carcinoma.
2001
Comparison of worm control strategies in grazing sheep in Denmark.
2001
A systematic overview of chemotherapy effects in colorectal cancer.
2001
The biochemical basis of anthelmintic action and resistance.
2001 Apr
Genes affecting the activity of nicotinic receptors involved in Caenorhabditis elegans egg-laying behavior.
2001 Apr
Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial.
2001 Apr 7
Amplified fragment length polymorphism analysis of genetic diversity of Haemonchus contortus during selection for drug resistance.
2001 Aug
Efficacy of combined chemotherapy against gastrointestinal nematodes and Fasciola hepatica in cattle.
2001 Aug 20
Effects of anthelmintics on the development of eggs of Angiostrongylus costaricensis in vitro.
2001 Dec
Prevalence of anthelmintic resistance in gastrointestinal nematodes of dairy goats under extensive management conditions in southwestern France.
2001 Dec
Regulation of distinct muscle behaviors controls the C. elegans male's copulatory spicules during mating.
2001 Dec 14
Multiple anthelmintic resistance in sheep.
2001 Dec 22-29
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
2001 Feb
North Central Cancer Treatment Group--Mayo Clinic trials in colon cancer.
2001 Feb
Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer.
2001 Jan
5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency.
2001 Jan 9
Adjuvant chemotherapy for colon cancer: the US experience.
2001 Jan-Feb
[Colonic cancer. Adjuvant therapy: the Italian experience].
2001 Jan-Feb
Partial purification and biochemical characterization of a heteromeric protein phosphatase 2A holoenzyme from maize (Zea mays L.) leaves that dephosphorylates C4 phosophoenolpyruvate carboxylase.
2001 Jul
Control of anthelmintic resistant endoparasites in a commercial sheep flock through parasite community replacement.
2001 Jun 12
Cloning and structural analysis of partial acetylcholine receptor subunit genes from the parasitic nematode Teladorsagia circumcincta.
2001 Jun 28
Anthelmintic resistance on goat farms in Georgia: efficacy of anthelmintics against gastrointestinal nematodes in two selected goat herds.
2001 Jun 28
Oxidative modification of rat liver 5'-nucleotidase: the mechanisms for protection and re-activation.
2001 Oct
Levamisole vs. cyclophosphamide for frequently-relapsing steroid-dependent nephrotic syndrome.
2001 Oct
Kinetic comparison of tissue non-specific and placental human alkaline phosphatases expressed in baculovirus infected cells: application to screening for Down's syndrome.
2002
Modulation of insulin transport in rat brain microvessel endothelial cells by an ecto-phosphatase activity.
2002
A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma.
2002 Apr 22
213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model.
2002 Apr 8
Characterization and cytochemical localization of an ATP diphosphohydrolase from Leishmania amazonensis promastigotes.
2002 Feb
Prevalence of levamisole and benzimidazole resistance in oesophagostomum populations of pig-breeding farms in North Rhine-Westphalia, Germany.
2002 Jan
Identification of molecular markers for the early detection of human squamous cell carcinoma of the uterine cervix.
2002 Jan 21
Patents

Sample Use Guides

The combination of ERGAMISOL (levamisole hydrochloride) and 5-fluorouracil is administered according to the following dosage schedule: Initial Therapy: Week 1 (3rd to 4th week post surgery): 5-fluorouracil 450 mg/m² i.v. push days 1 –5 and ERGAMISOL 50 mg orally t.i.d days 1 –3; Week 3 only ERGAMISOL 50 mg orally t.i.d days 1 –3. Therapy should commence 3 –4 weeks post surgery. 5-Fluorouracil (450 mg/m²) is administered by rapid i.v. injection for the first 5 days of Week 1. ERGAMISOL 50 mg tablet is administered orally three times a day for the first 3 days of Week 1, and again on the first 3 days of Week 3.
Route of Administration: Oral
In Vitro Use Guide
It was examined the immunological effects of levamisole in vitro. Experiments utilized peripheral blood mononuclear cells from normal donors incubated in the presence of increasing concentrations of levamisole (0.1 to 100 micrograms/ml). Levamisole had no consistent effect on induction of 2',5'-oligoadenylate synthetase activity or indoleamine-2,3-dioxygenase activity, or production of tumor necrosis factor. Levamisole had no effect on monocyte cytotoxicity or expression of HLA-DR, HLA-DQ, HLA-DP, and the Fc receptor. Similarly, levamisole had no significant effect on NK or LAK cytotoxicity or the immunological activation of T-lymphocytes, assessed by expression of CD3, CD4, CD8, CD16, CD25, and CD56. No significant enhancement in the expression of three tumor-associated antigens (880364, NRCO-4, and ING-1) and the intercellular adhesion molecule-1 (ICAM-1) antigen on four human cancer cell lines was observed following in vitro exposure to levamisole. In conclusion, was revealed, that levamisole was not a potent modulator of the immune parameters.
Name Type Language
LEVAMISOLE HYDROCHLORIDE
EP   GREEN BOOK   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   WHO-DD   WHO-IP  
USAN  
Official Name English
LEVAMISOLE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
LEVAMISOLE HYDROCHLORIDE [MART.]
Common Name English
R-12564
Code English
LEVAMISOLE HYDROCHLORIDE [USP-RS]
Common Name English
LEVAMISOLE HYDROCHLORIDE [MI]
Common Name English
LEVAMISOLE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
LEVAMISOLE HYDROCHLORIDE [WHO-DD]
Common Name English
LEVAMISOLI HYDROCHLORIDUM [WHO-IP LATIN]
Common Name English
LEVAMISOLE HYDROCHLORIDE [JAN]
Common Name English
IMIDAZO(2,1-B)THIAZOLE, 2,3,5,6-TETRAHYDRO-6-PHENYL-, MONOHYDROCHLORIDE, (S)-
Common Name English
SPARTAKON L
Common Name English
TETRAMISOLE HYDROCHLORIDE, (S)-
Common Name English
LEVAMISOLE HYDROCHLORIDE [WHO-IP]
Common Name English
LEVAMISOLE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
(-)-2,3,5,6-TETRAHYDRO-6-PHENYLIMIDAZO(2,1-B)THIAZOLE MONOHYDROCHLORIDE
Systematic Name English
ERGAMISOL
Brand Name English
LEVAMISOLE HYDROCHLORIDE [USAN]
Common Name English
L-NARPENOL
Common Name English
LEVAMISOLE HYDROCHLORIDE [GREEN BOOK]
Common Name English
R 12654
Code English
LEVAMISOLE HCL
Common Name English
R 12,564
Code English
NSC-177023
Code English
ASCARIDIL
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/05/324
Created by admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
CFR 21 CFR 520.1242E
Created by admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
NCI_THESAURUS C2141
Created by admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
CFR 21 CFR 556.350
Created by admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
Code System Code Type Description
CAS
16595-80-5
Created by admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
PRIMARY
DRUG BANK
DBSALT000822
Created by admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
PRIMARY
NCI_THESAURUS
C610
Created by admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
LEVAMISOLE HYDROCHLORIDE
Created by admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
PRIMARY Description: A white or almost white, crystalline powder. Solubility: Freely soluble in water; soluble in ethanol (~750 g/L) TS; slightly soluble in dichloromethane R. Category: Anthelminthic. Storage: Levamisole hydrochloride should be kept in a well-closed container, protected from light. Requirement: Levamisole hydrochloride contains not less than 98.5% and not more than 101.0% of C11H12N2S,HCl, calculated with reference to the dried substance.
EPA CompTox
16595-80-5
Created by admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
PRIMARY
ChEMBL
CHEMBL1454
Created by admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
PRIMARY
FDA UNII
DL9055K809
Created by admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
PRIMARY
PUBCHEM
27944
Created by admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
PRIMARY
EVMPD
SUB02902MIG
Created by admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
PRIMARY
USP_CATALOG
1359302
Created by admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
PRIMARY USP-RS
MERCK INDEX
M6781
Created by admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
PRIMARY Merck Index
RXCUI
227227
Created by admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
PRIMARY RxNorm
ECHA (EC/EINECS)
240-654-6
Created by admin on Fri Jun 25 20:55:21 UTC 2021 , Edited by admin on Fri Jun 25 20:55:21 UTC 2021
PRIMARY